Effects of cyclic versus daily hPTH(1-34) regimens on bone strength in association with BMD, biochemical markers, and bone structure in mice

Journal of Bone and Mineral Research

Volumn 21, Issue 2, 2006, Pages 274-282

  Iida Klein, Akiko ^a,b   Hughes, Christine ^a   Lu, Shi Shou ^a   Moreno, Annette ^a   Shen, Victor ^c   Dempster, David W ^a,b   Cosman, Felicia ^a,b   Lindsay, Robert ^a,b  

^a HELEN HAYES HOSPITAL   (United States)

^b College of Physicians and Surgeons ^*  (United States)

^c SkeleTech Inc   (United States)

Author keywords

BMD; Bone strength; Bone structure; Cyclic PTH regimen; Mice

Indexed keywords

BIOCHEMICAL MARKER; OSTEOCALCIN; PARATHYROID HORMONE[1-34]; PROTEIN MTRACP; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOMECHANICS; BONE DENSITY; BONE STRENGTH; BONE STRUCTURE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DUAL ENERGY X RAY ABSORPTIOMETRY; ECONOMIC EVALUATION; FEMALE; FEMUR; HORMONAL THERAPY; HORMONE ACTION; INJECTION; MOUSE; NONHUMAN; TIBIA; VERTEBRA; WEIGHT BEARING;

ACID PHOSPHATASE; ANIMALS; BIOLOGICAL MARKERS; BONE DENSITY; CALCIUM; DRUG ADMINISTRATION SCHEDULE; FEMALE; FEMUR; ISOENZYMES; MICE; MICE, INBRED C57BL; OSTEOCALCIN; OSTEOPOROSIS; PEPTIDE FRAGMENTS; SPINE; TERIPARATIDE; WEIGHT-BEARING;

EID: 33144482005     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/JBMR.051017     Document Type: Article

References (37)

1. Lindsay R, Nieves J, Formica C, Henneman E, Woelfert L, Shen V, Dempster D, Cosman F 1997 Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet 350:550-555.
2. Cosman F, Nieves J, Woelfert L, Formica C, Gordon S, Shen V, Lindsay R 2001 Parathyroid hormone added to established hormone therapy. Effects on vertebral fracture and maintenance of bone mass after PTH withdrawal. J Bone Miner Res 16:925-931.
3. Finkelstein JS, Hayes A, Hunzelman JL, Wyland JJ 2003 The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 349:1216-1226.
4. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH 2001 Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434-1441.
5. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genaut HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Gluer CC, Krueger K, Cohen FJ, Eckert S, Ensrud KE, Avioli LV, Lips P, Cummings SR 1999 Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene. Results from a 3-year randomized clinical trial. JAMA 282:637-645.
6. Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, Palermo L, Prineas R, Rubin SM, Scott JC, Vogt T, Wallace R, Yates AJ, LaCroix AZ 1998 Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures. JAMA 280:2077-2082.
7. McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, Adami S, Fogelman I, Diamond T, Eastell R, Meunier PJ, Reginster JY 2001 Effect of risedronate on the risk of hip fracture in elderly women. Hip intervention program study group. N Engl J Med 344:333-340.
8. Lindsay R, Cosman F, Zhou H, Bostrom M, Shen V, Cruz J, Nieves JW, Dempster DW 2006 A novel tetracycline labeling schedule for longitudinal evaluation of the short-term effects of anabolic therapy with a single iliac crest bone biopsy: Early actions of teriparatide. J Bone Miner Res (in press).
9. Cosman F, Nieves JW, Lucky MM, Zion M, Woelfert L, Lindsay R 2005 Daily versus cyclic PTH combined with alendronate versus alendronate alone for treatment of osteoporosis. N Engl J Med 353:566-575.
10. Gunness-Hey M, Hock JM 1989 Loss of the anabolic effect of parathyroid hormone on bone after discontinuation of hormone in rats. Bone 10:447-452.
11. Ma YL, Bryant HU, Zeng Q, Schmidt A, Hoover J, Cole HW, Yao W, Jee WS, Sato M 2003 New bone formation with teriparatide [human parathyroid hormone-(1-34)] is not retarded by long-term pretreatment with alendronate, estrogen, or raloxifene in ovariectomized rats. Endocrinology 144:2008-2015.
12. Ejersted C, Oxlund H, Eriksen EF, Andreassen TT 1998 Withdrawal of parathyroid hormone treatment causes rapid resorption of newly formed vertebral cancellous and endocortical bone in old rats. Bone 23:43-52.
13. Takano Y, Tanizawa T, Mashiba T, Endo N, Nishida S, Takahashi HE 1996 Maintaining bone mass by bisphosphonate incadronate disodium (YM175) sequential treatment after discontinuation of intermittent human parathyroid hormone (V-34) administration in ovariectomized rats. J Bone Miner Res 11:169-177.
14. Yamamoto N, Takahashi HE, Tanizawa T, Fujimoto R, Hara T, Tanaka S 1993 Maintenance of bone mass by physical exercise after discontinuation of intermittent hPTH(1-34) administration. Bone Miner 23:333-342.
15. Yokoyama K, Lu SS, Nieves J, Dempster DW, Lindsay R. Iida-Klein A 2002 Age is a major correlation factor affecting in vivo murine bone mineral density (BMD) for the longitudinal studies. J Bone Miner Res 17:S1;S365.
16. Iida-Klein A, Lu SS, Kapadia R, Burkhart M, Dempster DW, Lindsay R 2005 Short-term continuous infusion of human PTH1-34 fragment is catabolic with decreased trabecular connectivity density accompanied by hypercalcemia in C57BL/J6 mice. J Endocrinol 186:549-557.
17. Iida-Klein A, Zhou H, Lu SS, Levine L, Ducayen-Knowles M, Dempster DW, Nieves J, Lindsay R 2002 Anabolic action of human parathyroid hormone is skeletal site specific at the tissue and cellular levels in mice. J Bone Miner Res 17:808-816.
18. Iida-Klein A, Yokoyama K, Lu S-S, Dempster DW, Nieves J, Lindsay R 2003 Precision, accuracy and reproducibility of dual-X-ray absorptiometry (DXA) in mice in vivo. J Clin Densitom 6:25-33.
19. Brodt MD, Ellis CB, Silva MJ 1999 Growing C57B1/6 mice increase whole bone mechanical properties by increasing geometric and material properties. J Bone Miner Res 14:2159-2166.
20. Bain S, Tellefson S, Leninger R, Heggem M, Iuliucci J, Shen V 2001 Biomechanical testing as a rapid, primary efficacy endpoint in a murine model of postmenopausal osteoporosis. J Bone Miner Res 16:S1;S485.
21. Ma Y, Jee WS, Yuan Z, Wei W, Chen H, Pun S, Liang H, Lin C 1999 Parathyroid hormone and mechanical usage have a synergistic effect in rat tibial diaphyseal cortical bone. J Bone Miner Res 14:439-448.
22. Sekiya H, Mikuni-Takagaki Y, Kondoh T, Seto K 1999 Synergistic effect of PTH on the mechanical responses of human alveolar osteocytes. Biochem Biophys Res Commun 264:719-723.
23. Tobias JH, Chow JWM, Chambers TJ 1992 Opposite effects of insulin-like-growth factor-I on the formation of trabecular and cortical bone in adult female rats. Endocrinology 131:2387-2392.
24. Miyakoshi N, Kasukawa Y, Linkhart TA, Baylink DJ, Mohan S 2001 Evidence that anabolic effects of PTH on bone require IGF-I in growing mice. Endocrinology 142:4349-4356.
25. Bikle DD, Sakata T, Leary C, Elalieh H, Ginzinger D, Rosen CJ, Beamer W, Hajumdar S, Halloran BP 2002 Insulin-like growth factor I is required for the anabolic actions of parathyroid hormone on mouse bone. J Bone Miner Res 17:1570-1578.
26. Cummings SR, Black DM, Nevitt MC, Browner W, Cauley J, Ensrud K, Genant HK, Palermo L, Scott J, Vogt TM 1993 Bone density at various sites for predictions of hip fractures. Lancet 341:72-75.
27. Lang SM, Moyle DD, Berg CEW, Detorie N, Gilpin AT, Pappas NJ, Reynolds JC, Tkacik M, Waldron RL II 1988 Correlation of mechanical properties of vertebral trabecular bone with equivalent bone mineral density as measured by computed tomography. J Bone Joint Surg Am 70:1531-1538.
28. Melton LJ III, Atkinson EJ, O'Fallon WM, Wahner HW, Riggs BL 1993 Long-term fracture prediction by bone mineral density assessed at different skeletal sites. J Bone Miner Res 8:1227-1233.
29. Riggs BL, O'Fallon WM, Lane A, Hodgson SF, Wahner HW, Muhs J, Chao E, Melton LJ III 1994 Clinical trial of fluoride therapy in postmenopausal osteoporotic women: Extended observations and additional analysis. J Bone Miner Res 9:265-275.
30. Cummings SR, Karpf DB, Harris F, Genant HK, Ensrud K, LaCroix AZ, Black DM 2002 Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med 112:281-289.
31. Seeman E 2003 Periosteal bone formation-a neglected determinant of bone strength. N Engl J Med 349:320-323.
32. Ahlborg HG, Johnell O, Turner CH, Rannevik G, Karlsson MK 2003 Bone loss and bone size after menopause. N Engl J Med 349:327-334.
33. Duan Y, De Luca V, Seeman E 1999 Parathyroid hormone deficiency and excess: Similar effects on trabecular bone but different effects on cortical bone. J Clin Endocrinol Metab 84:718-722.
34. Zhou H, Iida-Klein A, Lu SS, Levine L, Ducayen-Knowles M, Dempster DW, Lindsay R 2003 The anabolic action of PTH on cortical and cancellous bone differs between axial and appendicular skeletal sites in mice. Bone 32:513-520.
35. Tanck E, Homminga J, van Lenthe GH, Huiskes R 2001 Increase in bone volume fraction precedes architectural adaptation in growing bone. Bone 28:650-654.
36. Misof BM, Roschger P, Cosman F, Kurland ES, Tesch W, Messmer P, Dempster DW, Nieves J, Shane E, Fratzl P, Klaushofer K, Bilesikian J, Lindsay R 2003 Effects of intermittent parathyroid hormone administration on bone mineralization density in iliac crest biopsies from patients with osteoporosis: A paired study before and after treatment. J Clin Endocrinol Metab 88:1150-1156.
37. Seeman E, Wahner HW, Offord KP, Kumar R, Johnson WJ, Riggs BL 1982 Differential effects of endocrine dysfunction on the axial and the appendicular skeleton. J Clin Invest 69:1302-1309.